Authors
Latest:
Enrollment: More Than NumbersPartnering with CROs and using a blinded independent central review can increase trial success.
Latest:
PK in Late Phase TrialsCollecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.
Latest:
Bridging US and China to Conquer CancerDuring the annual ASCO meeting in June, the US Chinese Anti-Cancer Association (USCACA) held its fourth annual meeting to discuss the emerging role of China in global clinical development of novel anti-cancer drugs.
Latest:
Emerging Opportunity in GuatemalaGuatemala is multi-ethnic, multilingual, and multi-cultural-ideal for international trials.
Latest:
PK in Late Phase TrialsCollecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.
Latest:
My 3 Key Reflections on Partnerships in Clinical Trials USA 2016Technology advancement has been breaking down traditional barriers and has provided an answer to how the industry can move forward. The Partnerships in Clinical Trials Conference in Boston drove home this approach with three key themes that were present at the event.
Latest:
Electronic Endpoint AdjudicationHow an integrated, EDC-based system can optimize the endpoint process.
Latest:
Rethinking Document SharingThe benefits of peer-to-peer networking over email, fax, FTP, and hosted solutions.
Latest:
Beware of Costly ConsequencesNoncompliance with the US Foreign Corrupt Practices Act carries heavy penalties.
Latest:
Reducing Risk Through Mitigation StrategiesProactive risk management helps pharma protect their product development investments and future.
Latest:
Reducing Risk Through Mitigation StrategiesProactive risk management helps pharma protect their product development investments and future.
Latest:
Oh No Not Again...Investigator training should not be a "one-off" session at the start of clinical trial.
Latest:
Triggered MonitoringAmong the many clinical development processes that need to be conducted in a smarter, more cost-effective manner, clinical data monitoring stands out as a promising area in which operational efficiencies can not only reduce costs but also improve research quality and patient safety.
Latest:
Information as a Strategic AssetUses for next generation information management, called health intelligence, in research.
Latest:
Digital Measures of Health: What’s in it for Patients?Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving meaningful impact for patients.
Latest:
Information as a Strategic AssetUses for next generation information management, called health intelligence, in research.
Latest:
Information in Action: DIA's Barbara Lopez KunzWilliam Looney speaks with DIA's Global Chief Executive to see how the organization is repositioning itself.
Latest:
Beware of Costly ConsequencesNoncompliance with the US Foreign Corrupt Practices Act carries heavy penalties.
Latest:
Trials in Latin AmericaAn overview of the clinical research landscape in this emerging region that also looks at its challenges.
Latest:
Reducing the Data Burden for Clinical InvestigatorsClinical trials have changed significantly in the past decade with increasingly large and complex global studies. Multi-center, multinational trials are common, with complicated treatment protocols, large staffs, and huge data sets muddling the clinical trial processes. With years of development time and millions in R&D invested in a new treatment before it reaches the trial stage, there is incredible pressure on investigators to deliver quality data.
Latest:
Enabling Digital Transformation: Managing External Clinical Data Sources to Advance Drug DevelopmentWith an increasing amount of diverse data that must now be collected and analyzed, the industry is faced with increasingly complex studies that present new challenges in data management.
Latest:
Sunshine Act's ImpactThe amendment addresses data concerns for both physicians and drug/device manufacturers.
